The forecasted sales for anti-infective medicine in Japan from 2024 to 2028 remain steady at 8.4 US Dollars Per Capita. This consistency suggests a plateau in demand or spending efficiency, showing no year-on-year variation or growth over the forecast period. In 2023, actual data would have provided a baseline, but its value isn't provided here. The compound annual growth rate (CAGR) over the past five years would indicate no growth, reflecting static market conditions or saturation.

Future trends to watch for:

Innovation in anti-infective products may disrupt the stagnant forecast.
Policy changes or health initiatives could impact sales positively or negatively.
Population aging and changing healthcare needs might influence future demand.